- Investing.com
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Metrics to compare | BJDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBJDXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.3x | −3.7x | −0.5x | |
PEG Ratio | 0.00 | −0.06 | 0.00 | |
Price/Book | 0.3x | 1.3x | 2.6x | |
Price / LTM Sales | - | 1.5x | 3.2x | |
Upside (Analyst Target) | - | 48.3% | 54.1% | |
Fair Value Upside | Unlock | 12.7% | 8.2% | Unlock |